Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015

“…No obstante, en la última década, ante el surgimiento y alta tasa de mortalidad en infecciones invasoras causadas por BGN-MR, polimixina B, en monoterapia o en combinación con otros antimicrobianos activos contra BGN-MR, permanece como el principal antimicrobiano usado para agentes de este tipo en nuestro medio 1,7,8 . Históricamente, la falla renal asociada al uso de polimixina B fluctúa entre 14 y 60% [8][9][10][11][12][13] . No obstante, estudios 8 www.sochinf.cl…”

Ventilator-Associated Pneumonia (VAP): Clinical Strategies, Treatment Challenges and Economic Concerns

“…Numerous stratagems have been illustrated to accomplish the various objectives including the incidence and risk of VAP and reduction in days of ventilation including Non-invasive Positive Pressure Ventilation (NPPV), weaning trials, sedation episodes, re-intubation avoidance, and an early tracheostomy. At the point when connected as a multimodal procedure by an interdisciplinary group, these intercessions are destined to be fruitful among children's and adults and have demonstrated viability in various regions of the world [46][47][48][49][50][51][52].…”

Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae

“…24,28,31 In many countries including the US, CMS is labeled in terms of "colistin base activity" (CBA), where 80 mg of CMS is equal to approximately 30 mg of CBA, a conversion factor of about 2.7. 25,32,33 It is notable that this is essentially a "possible amount" of active colistin that may be achieved in vivo, since the proportion of CMS that is actually converted to colistin in vitro differs considerably between patients as they eliminate the prodrug. 24,25,28,29 In other parts of the world, colistin is dosed in terms of international units (IU), whereas 1 million IUs D 30 mg of CBA.…”

“…Clinicians should use whichever dosing description is best understood in their country, but the use of mg of CMS should be avoided since this can lead to potentially fatal dosing errors. 33 CMS is efficiently removed by renal elimination via both glomerular filtration and tubular secretion. 24,25,27,29 Perhaps counterintuitively, high degrees of renal function are problematic with colistin use since achieving therapeutic concentrations of colistin is difficult, particularly if the patient is infected with an organism with an elevated MIC.…”